| Prev Close | 179.33 |
| Open | 183.82 |
| Day Low/High | 177.17 / 186.50 |
| 52 Wk Low/High | 6.26 / 189.40 |
| Volume | 2.21M |
Novavax, Inc. (NVAX)
185.26
5.90
3.30
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 74.09B |
| Market Cap | 13.63B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
China Headline Risk, Valuation Station and a Workday Play
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
Merck Is All In With a Threefold Approach to Covid-19
I've been long Merck for a long time, since way before this pandemic became part of our lives.
Floor Traders Return to NYSE, Novavax Vaccine News, Be Amphibious
The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.
Jim Cramer: It's Still Better to Be Safe Than Sorry
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.
Sell Signals, 'Operation Warp Speed,' Trading Notes
Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.
Jim Cramer: Let the Froth Wash Out
Let's look at the stocks that will get crushed and that you can't touch right now.
Vaccine Maker Novavax Shares Have Soared but Can It Continue?
The company has worked on two previous coronavirus vaccines as well as an Ebola vaccine.
Jim Cramer: The Cost of Staying Closed
We can't wait for a vaccine, but we can follow logical guidelines for staying as safe as possible, helping us avoid another Great Depression.
2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields
Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.
This Isn't a Forgiving Environment, Long or Short
It's not often you have both overnight and intraday gap risk, so be aware, and good luck out there.
Playing the Hand You're Dealt
Check out just a few of the year-to-date moves coming into Thursday on 8 companies you've never heard of before the last week or two.
Take a Poker Player's Approach to Playing Small Biotech Stocks
As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.
Midday Report: Crude Stockpiles Rise for First Week in Nine; Stocks Rise
Stocks move cautiously higher as investors wait for direction from a number of market-churning events tomorrow.
Novavax's Chart Looked Good, Until It Didn't
Things were looking up and then today happened.
Look to Costamare for Value in Shipping
It's safe to say these guys know what they are doing.
The Good, The Bad And The Ugly
"Such ingratitude, after all the times I saved your life." -- Blondie, THE GOOD THE BAD THE UGLY Let's run down the good, the bad and the ugly in today's market so far: THE GOOD Bonds are trading better today. The 10- and 30-year bond yields are dow...
Underlying Risks in Speculative Bio Techs Can't Be Overstated
I have followed Novavax for several years. After yesterday's market close the company announced the results of their Phase Three trial for a respiratory-virus drug. NVAX missed its goal, and the shares are trading down by about 80% ($8.40 to $1) i...
Bought Aerie Earlier? Congratulations
An update on some recent small biotech recommendations.
4 Biotechs Set to Provide a Shot in the Arm
Each company has approaching catalysts.
4 Biotechs Set to Provide a Shot in the Arm
Each company has approaching catalysts.
3 Biotech-Investing Mistakes to Avoid
These are the biggest errors that I've made over the years.
4 Small-Cap Biotechs With Big Stories to Tell
Watch these names as stability returns to the sector.
My Takeaways and Observations
Another strong market day. The issue of taxes was front and center today. Here are some of my takes: My Take on Corporate Taxes Man Up, Allergan Shareholders Who Loses in Pfizer/Allergan Deal's Demise? I remain manifestly bearish, in the belief ...
Buying Biotechs
The iShares Nasdaq Biotechnology ETF (IBB) has tumbled from nearly $400 a share early last summer to around $240 at last check, so I'm taking advantage of today's market schmeissing to purchase a small position in a biotech (biowreck?). I'm buying a...
Jim Cramer Still Likes Home Depot, Kroger, But Tough to Buy Them Now
Jim Cramer talks oil, Citigroup, burger joints and biotechs.
Market Wrap: Stocks Retreat on China Devaluation
However, utilities and some technology names bucked the trend.
